Search research articles
Contact Us
Filters
Showing results (81-90 of 161) with videos related to
Page
of 17
Sort By:
European Urology
|
March 4, 2018
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
Niven Mehra, David Dolling, Semini Sumanasuriya, et al.
Clinical Chemistry
|
May 15, 2020
Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study
Guillemette E Benoist, Inge M van Oort, Emmy Boerrigter, et al.
Clinical Genitourinary Cancer
|
June 2, 2016
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
David Lorente, Aurelius Omlin, Zafeiris Zafeiriou, et al.
Urologic Oncology
|
December 23, 2020
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with <sup>225</sup>Ac-PSMA-617 targeted alpha-radiation therapy
Maarten J van der Doelen, Niven Mehra, Inge M van Oort, et al.
Prostate Cancer and Prostatic Diseases
|
October 1, 2020
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology
Bastiaan M Privé, Bas Israël, Melline G M Schilham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2007
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer
Jeany M Rademaker-Lakhai, Laurens V Beerepoot, Niven Mehra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2023
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Sofie H Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi, et al.
The New England Journal of Medicine
|
April 29, 2020
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann de Bono, Joaquin Mateo, Karim Fizazi, et al.
Molecular Oncology
|
June 16, 2026
Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, et al.
European Urology
|
March 12, 2016
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer
Pasquale Rescigno, David Lorente, Diletta Bianchini, et al.
Page
of 17
Search research articles
Search
Showing results (81-90 of 161) with videos related to
Sort By:
Page
of 17
European Urology
|
March 4, 2018
Plasma Cell-free DNA Concentration and Outcomes from Taxane Therapy in Metastatic Castration-resistant Prostate Cancer from Two Phase III Trials (FIRSTANA and PROSELICA)
Niven Mehra, David Dolling, Semini Sumanasuriya, et al.
Clinical Chemistry
|
May 15, 2020
Prognostic Value of Novel Liquid Biomarkers in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Enzalutamide: A Prospective Observational Study
Guillemette E Benoist, Inge M van Oort, Emmy Boerrigter, et al.
Clinical Genitourinary Cancer
|
June 2, 2016
Castration-Resistant Prostate Cancer Tissue Acquisition From Bone Metastases for Molecular Analyses
David Lorente, Aurelius Omlin, Zafeiris Zafeiriou, et al.
Urologic Oncology
|
December 23, 2020
Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with <sup>225</sup>Ac-PSMA-617 targeted alpha-radiation therapy
Maarten J van der Doelen, Niven Mehra, Inge M van Oort, et al.
Prostate Cancer and Prostatic Diseases
|
October 1, 2020
Evaluating F-18-PSMA-1007-PET in primary prostate cancer and comparing it to multi-parametric MRI and histopathology
Bastiaan M Privé, Bas Israël, Melline G M Schilham, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
August 3, 2007
Phase I pharmacokinetic and pharmacodynamic study of the oral protein kinase C beta-inhibitor enzastaurin in combination with gemcitabine and cisplatin in patients with advanced cancer
Jeany M Rademaker-Lakhai, Laurens V Beerepoot, Niven Mehra, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 30, 2023
Early On-treatment Changes in Circulating Tumor DNA Fraction and Response to Enzalutamide or Abiraterone in Metastatic Castration-Resistant Prostate Cancer
Sofie H Tolmeijer, Emmy Boerrigter, Takayuki Sumiyoshi, et al.
The New England Journal of Medicine
|
April 29, 2020
Olaparib for Metastatic Castration-Resistant Prostate Cancer
Johann de Bono, Joaquin Mateo, Karim Fizazi, et al.
Molecular Oncology
|
June 16, 2026
Longitudinal genome-wide aneuploidy measurements in circulating cell-free DNA to predict lack of benefit from pembrolizumab in patients with metastatic urothelial cancer
Youssra Salhi, Stavros Makrodimitris, Sandra van Wilpe, et al.
European Urology
|
March 12, 2016
Prostate-specific Antigen Decline After 4 Weeks of Treatment with Abiraterone Acetate and Overall Survival in Patients with Metastatic Castration-resistant Prostate Cancer
Pasquale Rescigno, David Lorente, Diletta Bianchini, et al.
Page
of 17